Blockchain Registration Transaction Record
Tonix Pharmaceuticals Reports Q1 2025 Results and Progress Across Pipeline
Tonix Pharmaceuticals announces Q1 2025 results and progress across pipeline, highlighting advancements in fibromyalgia treatment. FDA decision for TNX-102 SL could revolutionize pain management. Important news for investors in biopharmaceutical sector.
This news matters as it showcases Tonix Pharmaceuticals' financial performance and advancements in developing innovative therapies for pain management and public health challenges. The FDA decision for TNX-102 SL could mark a significant milestone in fibromyalgia treatment, providing new options for patients. Investors and stakeholders in the biopharmaceutical industry should take note of Tonix's promising developments.
| Blockchain | Details |
|---|---|
| Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
| Transaction ID | 0x747ad918a4abdc7ab8a9aea393ecd2fcc81dd18cae34843af0a94d564fb4a9a2 |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | mielUxhT-c1c120f20c69abbcf961829a1a00c74e |